Stuart A. Arbuckle

2013

In 2013, Stuart A. Arbuckle earned a total compensation of $4.8M as EVP & Chief Commercial Officer at Vertex Pharmaceuticals, which was about the same as previous year.

Compensation breakdown

Non-Equity Incentive Plan$630,000
Option Awards$3,077,513
Salary$553,846
Stock Awards$544,988
Other$12,675
Total$4,819,022

Arbuckle received $3.1M in option awards, accounting for 64% of the total pay in 2013.

Arbuckle also received $630K in non-equity incentive plan, $553.8K in salary, $545K in stock awards and $12.7K in other compensation.

Rankings

In 2013, Stuart A. Arbuckle's compensation ranked 1,347th out of 12,286 executives tracked by ExecPay. In other words, Arbuckle earned more than 89.0% of executives.

ClassificationRankingPercentile
All
1,347
out of 12,286
89th
Division
Manufacturing
433
out of 4,614
91st
Major group
Chemicals And Allied Products
118
out of 1,466
92nd
Industry group
Drugs
78
out of 1,160
93rd
Industry
Pharmaceutical Preparations
69
out of 890
92nd
Source: SEC filing on April 29, 2016.

Arbuckle's colleagues

We found four more compensation records of executives who worked with Stuart A. Arbuckle at Vertex Pharmaceuticals in 2013.

2013

Jeffrey Leiden

Vertex Pharmaceuticals

Chief Executive Officer

2013

Kenneth Horton

Vertex Pharmaceuticals

Chief Legal Officer

2013

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2013

Peter Mueller

Vertex Pharmaceuticals

Chief Scientific Officer

News

In-depth

You may also like